Advertisement

Nicotine Chemistry, Metabolism, Kinetics and Biomarkers

  • Neal L. Benowitz
  • Janne Hukkanen
  • Peyton JacobIII
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 192)

Abstract

Nicotine underlies tobacco addiction, influences tobacco use patterns, and is used as a pharmacological aid to smoking cessation. The absorption, distribution and disposition characteristics of nicotine from tobacco and medicinal products are reviewed. Nicotine is metabolized primarily by the liver enzymes CYP2A6, UDPglucuronosyltransfease (UGT), and flavin-containing monooxygenase (FMO). In addition to genetic factors, nicotine metabolism is influenced by diet and meals, age, sex, use of estrogen-containing hormone preparations, pregnancy and kidney disease, other medications, and smoking itself. Substantial racial/ethnic differences are observed in nicotine metabolism, which are likely influenced by both genetic and environmental factors. The most widely used biomarker of nicotine intake is cotinine, which may be measured in blood, urine, saliva, hair, or nails. The current optimal plasma cotinine cut-point to distinguish smokers from non-smokers in the general US population is 3 ng ml−1. This cut-point is much lower than that established 20 years ago, reflecting less secondhand smoke exposure due to clear air policies and more light or occasional smoking.

Keywords

Nicotine Replacement Therapy Grapefruit Juice Environmental Tobacco Smoke Exposure Nicotine Concentration Nicotine Intake 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Al-Delaimy WK, Crane J, Woodward A (2002) Is the hair nicotine level a more accurate biomarker of environmental tobacco smoke exposure than urine cotinine? J Epidemiol Community Health 56(1):66–71PubMedGoogle Scholar
  2. Armitage A, Dollery C, Houseman T, Kohner E, Lewis PJ, Turner D (1978) Absorption of nicotine from small cigars. Clin Pharmacol Ther 23(2):143–151PubMedGoogle Scholar
  3. Armstrong DW, Wang X, Ercal N (1998) Enantiomeric composition of nicotine in smokeless tobacco, medicinal products, and commercial reagents. Chirality 10:587–591Google Scholar
  4. Asimus S, Hai TN, Van Huong N, Ashton M (2008) Artemisin and CYP2A6 activity in healthy subjects. Eur J Clin Pharmacol 64:283–292PubMedGoogle Scholar
  5. Bendayan R, Sullivan JT, Shaw C, Frecker RC, Sellers EM (1990) Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans. Eur J Clin Pharmacol 38(2):165–169PubMedGoogle Scholar
  6. Benowitz NL (1990) Clinical pharmacology of inhaled drugs of abuse: implications in understanding nicotine dependence. NIDA Res Monogr 99:12–29PubMedGoogle Scholar
  7. Benowitz NL (1996) Cotinine as a biomarker of environmental tobacco smoke exposure. Epidemiol Rev 18(2):188–204PubMedGoogle Scholar
  8. Benowitz NL, Jacob P 3rd (1984) Daily intake of nicotine during cigarette smoking. Clin Pharmacol Ther 35(4):499–504PubMedGoogle Scholar
  9. Benowitz NL, Jacob P 3rd (1985) Nicotine renal excretion rate influences nicotine intake during cigarette smoking. J Pharmacol Exp Ther 234(1):153–155PubMedGoogle Scholar
  10. Benowitz NL, Jacob P 3rd (1993) Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers. Clin Pharmacol Ther 53(3):316–323PubMedGoogle Scholar
  11. Benowitz NL, Jacob P 3rd (1994) Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin Pharmacol Ther 56(5):483–493PubMedGoogle Scholar
  12. Benowitz NL, Jacob P 3rd (2000) Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism. Clin Pharmacol Ther 67(6):653–659PubMedGoogle Scholar
  13. Benowitz NL, Jacob P 3rd (2001) Trans-3′-hydroxycotinine: disposition kinetics, effects and plasma levels during cigarette smoking. Br J Clin Pharmacol 51(1):53–59PubMedGoogle Scholar
  14. Benowitz NL, Jacob P 3rd, Jones RT, Rosenberg J (1982a) Interindividual variability in the metabolism and cardiovascular effects of nicotine in man. J Pharmacol Exp Ther 221(2):368–372Google Scholar
  15. Benowitz NL, Kuyt F, Jacob P 3rd (1982b) Circadian blood nicotine concentrations during cigarette smoking. Clin Pharmacol Ther 32(6):758–764Google Scholar
  16. Benowitz NL, Jacob P 3rd, Savanapridi C (1987) Determinants of nicotine intake while chewing nicotine polacrilex gum. Clin Pharmacol Ther 41(4):467–473PubMedGoogle Scholar
  17. Benowitz NL, Porchet H, Sheiner L, Jacob P 3rd (1988) Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin Pharmacol Ther 44(1):23–28PubMedGoogle Scholar
  18. Benowitz NL, Jacob P 3rd, Fong I, Gupta S (1994) Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. J Pharmacol Exp Ther 268(1):296–303PubMedGoogle Scholar
  19. Benowitz NL, Perez-Stable EJ, Fong I, Modin G, Herrera B, Jacob P 3rd (1999) Ethnic differences in N-glucuronidation of nicotine and cotinine. J Pharmacol Exp Ther 291(3):1196–1203PubMedGoogle Scholar
  20. Benowitz NL, Jacob P 3rd, Ahijevych K, Jarvis MJ, Hall S, LeHouezec J, Hansson A, Lichtenstein E, Henningfield J, Tsoh J, Hurt RD, Velicer W (2002a) Biochemical verification of tobacco use and cessation. Nicotine and Tobacco Research 4:149–159Google Scholar
  21. Benowitz NL, Perez-Stable EJ, Herrera B, Jacob P 3rd (2002b) Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans. J Natl Cancer Inst 94(2):108–115Google Scholar
  22. Benowitz NL, Herrera B, Jacob P, 3rd (2004) Mentholated cigarette smoking inhibits nicotine metabolism. J Pharmacol Exp Ther 310:1208–1215PubMedGoogle Scholar
  23. Benowitz NL, Lessov-Schlaggar CN, Swan GE, Jacob P 3rd (2006) Female sex and oral contraceptive use accelerate nicotine metabolism. Clin Pharmacol Ther 79(5):480–488PubMedGoogle Scholar
  24. Benowitz N, Bernert JT, Caraballo RS, Holiday DB, Wang J (2008a) Optimal Serum Cotinine Levels to Distinguish Cigarette Smokers and Non-Smokers within Different Racial/Ethnic Groups in the United States Between 1999–2004. Am J Epidemiol (in press)Google Scholar
  25. Benowitz N, Lessov-Schlaggar C, Swan G (2008b) Genetic Influences in the Variation in Renal Clearance of Nicotine and Cotinine. Clin Pharmacol Ther 84(2):243–247Google Scholar
  26. Breese CR, Marks MJ, Logel J, Adams CE, Sullivan B, Collins AC, Leonard S (1997) Effect of smoking history on [3H]nicotine binding in human postmortem brain. J Pharmacol Exp Ther 282(1):7–13PubMedGoogle Scholar
  27. Byrd GD, Chang KM, Greene JM, deBethizy JD (1992) Evidence for urinary excretion of glucuronide conjugates of nicotine, cotinine, and trans-3′-hydroxycotinine in smokers. Drug Metab Dispos 20(2):192–197PubMedGoogle Scholar
  28. Byrd GD, Uhrig MS, deBethizy JD, Caldwell WS, Crooks PA, Ravard A, Riggs R (1994) Direct determination of cotinine-N-glucuronide in urine using thermospray liquid chromatography/mass spectrometry. Biol Mass Spectrom 23(2):103–107PubMedGoogle Scholar
  29. Caraballo RS, Giovino GA, Pechacek TF, Mowery PD, Richter PA, Strauss WJ, Sharp DJ, Eriksen MP, Pirkle JL, Maurer KR (1998) Racial and ethnic differences in serum cotinine levels of cigarette smokers: Third National Health and Nutrition Examination Survey, 1988–1991. JAMA 280(2):135–139PubMedGoogle Scholar
  30. Cashman JR, Park SB, Yang ZC, Wrighton SA, Jacob P, 3rd, Benowitz NL (1992) Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N′-oxide. Chem Res Toxicol 5(5):639–646PubMedGoogle Scholar
  31. Choi JH, Dresler CM, Norton MR, Strahs KR (2003) Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine Tob Res 5(5):635–644PubMedGoogle Scholar
  32. Collier AM, Goldstein GM, Shrewsbury RP, Davis SM, Koch GG, Zhang C-A, Benowitz NL, Lewtas J, Williams RW (1994) Cotinine elimination and its use as a biomarker in young children involuntarily exposed to environmental tobacco smoke. Indoor Environ 3:353–359Google Scholar
  33. Crawford EL, Weaver DA, DeMuth JP, Jackson CM, Khuder SA, Frampton MW, Utell MJ, Thilly WG, Willey JC (1998) Measurement of cytochrome P450 2A6 and 2E1 gene expression in primary human bronchial epithelial cells. Carcinogenesis 19(10):1867–1871PubMedGoogle Scholar
  34. Dahlstrom A, Lundell B, Curvall M, Thapper L (1990) Nicotine and cotinine concentrations in the nursing mother and her infant. Acta Paediatr Scand 79(2):142–147PubMedGoogle Scholar
  35. de Leon J, Diaz FJ, Rogers T, Browne D, Dinsmore L, Ghosheh OH, Dwoskin LP, Crooks PA (2002) Total cotinine in plasma: a stable biomarker for exposure to tobacco smoke. J Clin Psychopharmacol 22(5):496–501PubMedGoogle Scholar
  36. Dehn DL, Claffey DJ, Duncan MW, Ruth JA (2001) Nicotine and cotinine adducts of a melanin intermediate demonstrated by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Chem Res Toxicol 14(3):275–279PubMedGoogle Scholar
  37. Dempsey DA, Benowitz NL (2001) Risks and benefits of nicotine to aid smoking cessation in pregnancy. Drug Saf 24(4):277–322PubMedGoogle Scholar
  38. Dempsey D, Jacob P, 3rd, Benowitz NL (2000) Nicotine metabolism and elimination kinetics in newborns. Clin Pharmacol Ther 67(5):458–465PubMedGoogle Scholar
  39. Dempsey D, Jacob P, 3rd, Benowitz NL (2002) Accelerated metabolism of nicotine and cotinine in pregnant smokers. J Pharmacol Exp Ther 301(2):594–598PubMedGoogle Scholar
  40. Dempsey D, Tutka P, Jacob P, 3rd, Allen F, Schoedel K, Tyndale RF, Benowitz NL (2004) Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther 76:64–72PubMedGoogle Scholar
  41. Denton TT, Zhang X, Cashman JR (2004) Nicotine-related alkaloids and metabolites as inhibitors of human cytochrome P-450 2A6. Biochem Pharmacol 67(4):751–756PubMedGoogle Scholar
  42. English PB, Eskenazi B, Christianson RE (1994) Black-white differences in serum cotinine levels among pregnant women and subsequent effects on infant birthweight. Am J Public Health 84(9):1439–1443PubMedGoogle Scholar
  43. Fant RV, Henningfield JE, Shiffman S, Strahs KR, Reitberg DP (2000) A pharmacokinetic crossover study to compare the absorption characteristics of three transdermal nicotine patches. Pharmacol Biochem Behav 67(3):479–482PubMedGoogle Scholar
  44. Florescu A, Ferrence R, Einarson TR, Selby P, Kramer M, Woodruff S, Grossman L, Rankin A, Jacqz-Aigrain E, Koren G (2007) Reference values for hair cotinine as a biomarker of active and passive smoking in women of reproductive age, pregnant women, children, and neonates: systematic review and meta-analysis. Ther Drug Monit 29(4):437–446PubMedGoogle Scholar
  45. Giovino G, Sidney S, Gfroerer J, O'Malley P, Allen J, Richter P, Ph DK (2004) Epidemiology of menthol cigarette use. Nicotine Tob Res 6(Suppl 1):S67–81PubMedGoogle Scholar
  46. Gori GB, Benowitz NL, Lynch CJ (1986) Mouth versus deep airways absorption of nicotine in cigarette smokers. Pharmacol Biochem Behav 25(6):1181–1184PubMedGoogle Scholar
  47. Gourlay SG, Benowitz NL (1996) The benefits of stopping smoking and the role of nicotine replacement therapy in older patients. Drugs Aging 9(1):8–23PubMedGoogle Scholar
  48. Gourlay SG, Benowitz NL (1997) Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine. Clin Pharmacol Ther 62(4):453–463PubMedGoogle Scholar
  49. Gow PJ, Ghabrial H, Smallwood RA, Morgan DJ, Ching MS (2001) Neonatal hepatic drug elimination. Pharmacol Toxicol 88(1):3–15PubMedGoogle Scholar
  50. Gries JM, Benowitz N, Verotta D (1996) Chronopharmacokinetics of nicotine. Clin Pharmacol Ther 60(4):385–395PubMedGoogle Scholar
  51. Guthrie SK, Zubieta JK, Ohl L, Ni L, Koeppe RA, Minoshima S, Domino EF (1999) Arterial/venous plasma nicotine concentrations following nicotine nasal spray. Eur J Clin Pharmacol 55(9):639–643PubMedGoogle Scholar
  52. Hatsukami DK, Hecht SS, Hennrikus DJ, Joseph AM, Pentel PR (2003) Biomarkers of tobacco exposure or harm: application to clinical and epidemiological studies. 25–26 October 2001, Minneapolis, Minnesota. Nicotine Tob Res 5(3):387–396PubMedGoogle Scholar
  53. Hecht SS (2003) Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 3(10):733–744PubMedGoogle Scholar
  54. Hecht SS, Carmella SG, Chen M, Dor Koch JF, Miller AT, Murphy SE, Jensen JA, Zimmerman CL, Hatsukami DK (1999a) Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation. Cancer Res 59(3):590–596Google Scholar
  55. Hecht SS, Carmella SG, Murphy SE (1999b) Effects of watercress consumption on urinary metabolites of nicotine in smokers. Cancer Epidemiol Biomarkers Prev 8(10):907–913Google Scholar
  56. Hecht SS, Hochalter JB, Villalta PW, Murphy SE (2000) 2′-Hydroxylation of nicotine by cytochrome P450 2A6 and human liver microsomes: formation of a lung carcinogen precursor. Proc Natl Acad Sci USA 97(23):12493–12497PubMedGoogle Scholar
  57. Henningfield JE, Keenan RM (1993) Nicotine delivery kinetics and abuse liability. J Consult Clin Psychol 61(5):743–750PubMedGoogle Scholar
  58. Henningfield JE, Stapleton JM, Benowitz NL, Grayson RF, London ED (1993) Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend 33(1):23–29PubMedGoogle Scholar
  59. Higashi E, Fukami T, Itoh M, Kyo S, Inoue M, Yokoi T, Nakajima M (2007) Human CYP2A6 is induced by estrogen via estrogen receptor. Drug Metab Dispos 35:1935–1941PubMedGoogle Scholar
  60. Hukkanen J, Vaisanen T, Lassila A, Piipari R, Anttila S, Pelkonen O, Raunio H, Hakkola J (2003) Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells. J Pharmacol Exp Ther 304(2):745–752PubMedGoogle Scholar
  61. Hukkanen J, Dempsey D, Jacob P, 3rd, Benowitz NL (2005a) Effect of pregnancy on a measure of FMO3 activity. Br J Clin Pharmacol 60(2):224–226Google Scholar
  62. Hukkanen J, Gourlay SG, Kenkare S, Benowitz NL (2005b) Influence of menstrual cycle on cytochrome P450 2A6 activity and cardiovascular effects of nicotine. Clin Pharmacol Ther 77(3):159–169Google Scholar
  63. Hukkanen J, Jacob P 3rd, Benowitz NL (2005c) Metabolism and disposition kinetics of nicotine. Pharmacol Rev 57(1):79–115Google Scholar
  64. Hukkanen J, Jacob P 3rd, Benowitz NL (2006) Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance. Clin Pharmacol Ther 80(5):522–530PubMedGoogle Scholar
  65. Hurt RD, Dale LC, Fredrickson PA, Caldwell CC, Lee GA, Offord KP, Lauger GG, Marusic Z, Neese LW, Lundberg TG (1994) Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement. JAMA 271(8):595–600PubMedGoogle Scholar
  66. Jacob P, 3rd, Benowitz NL (1991) Oxidative metabolism of nicotine in vivo. In: F. Adlkofer, K. Thurau (eds) Effects of nicotine on biological systems. Birkhauser Verlag, Basel, pp 35–44Google Scholar
  67. Jacob P, 3rd, Shulgin AT, Benowitz NL (1990) Synthesis of (3′R, 5′S)-trans-3′-hydroxycotinine, a major metabolite of nicotine. Metabolic formation of 3′-hydroxycotinine in humans is highly stereoselective. J Med Chem 33(7):1888–1891PubMedGoogle Scholar
  68. Jacob P, 3rd, Yu L, Shulgin AT, Benowitz NL (1999) Minor tobacco alkaloids as biomarkers for tobacco use: comparison of users of cigarettes, smokeless tobacco, cigars, and pipes. Am J Public Health 89(5):731–736PubMedGoogle Scholar
  69. Jacob P, 3rd, Hatsukami D, Severson H, Hall S, Yu L, Benowitz NL (2002) Anabasine and anatabine as biomarkers for tobacco use during nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev 11(12):1668–1673PubMedGoogle Scholar
  70. Jarvis MJ, Boreham R, Primatesta P, Feyerabend C, Bryant A (2001) Nicotine yield from machinesmoked cigarettes and nicotine intakes in smokers: evidence from a representative population survey. J Natl Cancer Inst 93(2):134–138PubMedGoogle Scholar
  71. Johansson CJ, Olsson P, Bende M, Carlsson T, Gunnarsson PO (1991) Absolute bioavailability of nicotine applied to different nasal regions. Eur J Clin Pharmacol 41(6):585–588PubMedGoogle Scholar
  72. Johnstone E, Benowitz N, Cargill A, Jacob R, Hinks L, Day I, Murphy M, Walton R (2006) Determinants of the rate of nicotine metabolism and effects on smoking behavior. Clin Pharmacol Ther 80(4):319–330PubMedGoogle Scholar
  73. Kandel DB, Hu MC, Schaffran C, Udry JR, Benowitz NL (2007) Urine nicotine metabolites and smoking behavior in a multiracial/multiethnic national sample of young adults. Am J Epidemiol 165(8):901–910PubMedGoogle Scholar
  74. Kozlowski LT, Mehta NY, Sweeney CT, Schwartz SS, Vogler GP, Jarvis MJ, West RJ (1998) Filter ventilation and nicotine content of tobacco in cigarettes from Canada, the United Kingdom, and the United States. Tob Control 7(4):369–375PubMedGoogle Scholar
  75. Krul C, Hageman G (1998) Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 709(1):27–34PubMedGoogle Scholar
  76. Kyerematen GA, Morgan M, Warner G, Martin LF, Vesell ES (1990) Metabolism of nicotine by hepatocytes. Biochem Pharmacol 40(8):1747–1756PubMedGoogle Scholar
  77. Le Gal A, Dreano Y, Lucas D, Berthou F (2003) Diversity of selective environmental substrates for human cytochrome P450 2A6: alkoxyethers, nicotine, coumarin, N-nitrosodiethylamine, and N-nitrosobenzylmethylamine. Toxicol Lett 144(1):77–91PubMedGoogle Scholar
  78. Lee BL, Benowitz NL, Jacob P 3rd (1987) Influence of tobacco abstinence on the disposition kinetics and effects of nicotine. Clin Pharmacol Ther 41(4):474–479PubMedGoogle Scholar
  79. Lee BL, Jacob P 3rd, Jarvik ME, Benowitz NL (1989) Food and nicotine metabolism. Pharmacol Biochem Behav 33(3):621–625PubMedGoogle Scholar
  80. Leete E (1983) Biosynthesis and metabolism of the tobacco alkaloids. In: Pelletier SW (ed) Alkaloids: chemical and biological perspectives. Wiley, New York, pp 85–152Google Scholar
  81. Leong JW, Dore ND, Shelley K, Holt EJ, Laing IA, Palmer LJ, LeSouef PN (1998) The elimination half-life of urinary cotinine in children of tobacco-smoking mothers. Pulm Pharmacol Ther 11(4):287–290PubMedGoogle Scholar
  82. Lerman C, Tyndale R, Patterson F, Wileyto EP, Shields PG, Pinto A, Benowitz N (2006) Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther 79(6):600–608PubMedGoogle Scholar
  83. Lindell G, Lunell E, Graffner H (1996) Transdermally administered nicotine accumulates in gastric juice. Eur J Clin Pharmacol 51(3–4):315–318PubMedGoogle Scholar
  84. Liston HL, Markowitz JS, DeVane CL (2001) Drug glucuronidation in clinical psychopharmacology. J Clin Psychopharmacol 21(5):500–515PubMedGoogle Scholar
  85. Lunell E, Molander L, Ekberg K, Wahren J (2000) Site of nicotine absorption from a vapour inhaler-comparison with cigarette smoking. Eur J Clin Pharmacol 55(10):737–741PubMedGoogle Scholar
  86. MacDougall JM, Fandrick K, Zhang X, Serafin SV, Cashman JR (2003) Inhibition of human liver microsomal (S)-nicotine oxidation by (–)-menthol and analogues. Chem Res Toxicol 16(8):988–993PubMedGoogle Scholar
  87. Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, Downey AD, Czerwinski M, Forster J, Ribadeneira MD, Gan LS, LeCluyse EL, Zech K, Robertson P, Jr., Koch P, Antonian L, Wagner G, Yu L, Parkinson A (2003) Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 31(4):421–431PubMedGoogle Scholar
  88. McBride JS, Altman DG, Klein M, White W (1998) Green tobacco sickness. Tob Control 7(3):294–298PubMedGoogle Scholar
  89. McCusker K, McNabb E, Bone R (1982) Plasma nicotine levels in pipe smokers. JAMA 248(5):577–578PubMedGoogle Scholar
  90. McKennis H, Jr., Turnbull LB, Bowman ER, Tamaki E (1963) The synthesis of hydroxycotinine and studies on its structure. J Org Chem 28:383–387Google Scholar
  91. McNabb ME (1984) Chewing nicotine gum for 3 months: what happens to plasma nicotine levels? Can Med Assoc J 131(6)589–592PubMedGoogle Scholar
  92. McNabb ME, Ebert RV, McCusker K (1982) Plasma nicotine levels produced by chewing nicotine gum. JAMA 248(7):865–868PubMedGoogle Scholar
  93. Messina ES, Tyndale RF, Sellers EM (1997) A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 282(3):1608–1614PubMedGoogle Scholar
  94. Meunier V, Bourrie M, Julian B, Marti E, Guillou F, Berger Y, Fabre G (2000) Expression and induction of CYP1A1/1A2, CYP2A6 and CYP3A4 in primary cultures of human hepatocytes: a 10-year follow-up. Xenobiotica 30(6)589–607PubMedGoogle Scholar
  95. Molander L, Lunell E, Andersson SB, Kuylenstierna F (1996) Dose released and absolute bioavailability of nicotine from a nicotine vapor inhaler. Clin Pharmacol Ther 59(4):394–400PubMedGoogle Scholar
  96. Molander L, Hansson A, Lunell E, Alainentalo L, Hoffmann M, Larsson R (2000) Pharmacokinetics of nicotine in kidney failure. Clin Pharmacol Ther 68(3):250–260PubMedGoogle Scholar
  97. Molander L, Hansson A, Lunell E (2001) Pharmacokinetics of nicotine in healthy elderly people. Clin Pharmacol Ther 69(1):57–65PubMedGoogle Scholar
  98. Munzel PA, Schmohl S, Heel H, Kalberer K, Bock-Hennig BS, Bock KW (1999) Induction of human UDP glucuronosyltransferases (UGT1A6, UGT1A9, and UGT2B7) by tbutylhydroquinone and 2,3,7,8-tetrachlorodibenzo-p-dioxin in Caco-2 cells. Drug Metab Dispos 27(5):569–573PubMedGoogle Scholar
  99. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N, Kamataki T, Kuroiwa Y (1996) Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 24(11):1212–1217PubMedGoogle Scholar
  100. Neurath GB (1994) Aspects of the oxidative metabolism of nicotine. Clin Investig 72(3):190–195PubMedGoogle Scholar
  101. Neurath GB, Dunger M, Orth D, Pein FG (1987) Trans-3′-hydroxycotinine as a main metabolite in urine of smokers. Int Arch Occup Environ Health 59(2):199–201PubMedGoogle Scholar
  102. Neurath GB, Orth D, Pein FG (1991) Detection of nornicotine in human urine after infusion of nicotine. In: Adlkofer F, Thurau K (eds) Effects of nicotine on biological systems. Birkhauser Verlag, Basel, pp 45–49Google Scholar
  103. Nolin TD, Frye RF, Matzke GR (2003) Hepatic drug metabolism and transport in patients with kidney disease. Am J Kidney Dis 42(5):906–925PubMedGoogle Scholar
  104. Obach RS (2004) Potent inhibition of human liver aldehyde oxidase by raloxifene. Drug Metab Dispos 32(1):89–97PubMedGoogle Scholar
  105. Pankow JF (2001) A consideration of the role of gas/particle partitioning in the deposition of nicotine and other tobacco smoke compounds in the respiratory tract. Chem Res Toxicol 14(11):1465–1481PubMedGoogle Scholar
  106. Park SB, Jacob P, 3rd, Benowitz NL, Cashman JR (1993) Stereoselective metabolism of (S)-(-)-nicotine in humans: formation of trans-(S)-(-)-nicotine N-1′-oxide. Chem Res Toxicol 6(6):880–888PubMedGoogle Scholar
  107. Patterson F, Benowitz N, Shields P, Kaufmann V, Jepson C, Wileyto P, Kucharski S, Lerman C (2003) Individual differences in nicotine intake per cigarette. Cancer Epidemiol Biomarkers Prev 12(5):468–471PubMedGoogle Scholar
  108. Patterson F, Schnoll R, Wileyto E, Pinto A, Epstein L, Shields P, Hawk L, Tyndale R, Benowitz N, Lerman C (2008) Toward Personalized Therapy for Smoking Cessation: A Randomized Placebo-controlled Trial of Bupropion. Clin Pharmacol Ther 84(3):320–325PubMedGoogle Scholar
  109. Perez-Stable EJ, Herrera B, Jacob P 3rd, Benowitz NL (1998) Nicotine metabolism and intake in black and white smokers. JAMA 280(2):152–156PubMedGoogle Scholar
  110. Perry RJ, Griffiths W, Dextraze P, Solomon RJ, Trebbin WM (1984) Elevated nicotine levels in patients undergoing hemodialysis. A role in cardiovascular mortality and morbidity? Am J Med 76(2):241–246PubMedGoogle Scholar
  111. Perry DC, Davila-Garcia MI, Stockmeier CA, Kellar KJ (1999) Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. J Pharmacol Exp Ther 289(3):1545–1552PubMedGoogle Scholar
  112. Rae JM, Johnson MD, Lippman ME, Flockhart DA (2001) Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 299(3):849–857PubMedGoogle Scholar
  113. Rebagliato M, Bolumar F, Florey Cdu V, Jarvis MJ, Perez-Hoyos S, Hernandez-Aguado I, Avino MJ (1998) Variations in cotinine levels in smokers during and after pregnancy. Am J Obstet Gynecol 178(3):568–571PubMedGoogle Scholar
  114. Ren Q, Murphy SE, Zheng Z, Lazarus P (2000) O-Glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1- (3-pyridyl)-1-butanol (NNAL) by human UDP-glucuronosyltransferases 2B7 and 1A9. Drug Metab Dispos 28(11):1352–1360PubMedGoogle Scholar
  115. Rose JE, Behm FM, Westman EC, Coleman RE (1999) Arterial nicotine kinetics during cigarette smoking and intravenous nicotine administration: implications for addiction. Drug Alcohol Depend 56(2):99–107PubMedGoogle Scholar
  116. Runkel M, Bourian M, Tegtmeier M, Legrum W (1997) The character of inhibition of the metabolism of 1,2-benzopyrone (coumarin) by grapefruit juice in human. Eur J Clin Pharmacol 53(3–4):265–269PubMedGoogle Scholar
  117. Schneider NG, Olmstead R, Mody FV, Doan K, Franzon M, Jarvik ME, Steinberg C (1995) Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial. Addiction 90(12):1671–1682PubMedGoogle Scholar
  118. Schneider NG, Olmstead RE, Franzon MA, Lunell E (2001) The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments. Clin Pharmacokinet 40(9):661–684PubMedGoogle Scholar
  119. Schoedel KA, Sellers EM, Palmour R, Tyndale RF (2003) Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration. Mol Pharmacol 63(1):96–104PubMedGoogle Scholar
  120. Selby P, Hackman R, Kapur B, Klein J, Koren G (2001) Heavily smoking women who cannot quit in pregnancy: evidence of pharmacokinetic predisposition. Ther Drug Monit 23(3):189–191PubMedGoogle Scholar
  121. Sellers EM, Kaplan HL, Tyndale RF (2000) Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clin Pharmacol Ther 68(1):35–43PubMedGoogle Scholar
  122. Sellers EM, Ramamoorthy Y, Zeman MV, Djordjevic MV, Tyndale RF (2003) The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo. Nicotine Tob Res 5(6):891–899PubMedGoogle Scholar
  123. Shigenaga MK, Trevor AJ, Castagnoli N Jr (1988) Metabolism-dependent covalent binding of (S)-[5-3H]nicotine to liver and lung microsomal macromolecules. Drug Metab Dispos 16(3):397–402PubMedGoogle Scholar
  124. Siegmund B, Leitner E, Pfannhauser W (1999) Determination of the nicotine content of various edible nightshades (Solanaceae) and their products and estimation of the associated dietary nicotine intake. J Agric Food Chem 47(8):3113–3120PubMedGoogle Scholar
  125. Stepanov I, Hecht SS, Lindgren B, Jacob P 3rd, Wilson M, Benowitz NL (2007) Relationship of human toenail nicotine, cotinine, and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol to levels of these biomarkers in plasma and urine. Cancer Epidemiol Biomarkers Prev 16(7):1382–1386PubMedGoogle Scholar
  126. Swan GE, Benowitz NL, Lessov CN, Jacob P, 3rd, Tyndale RF, Wilhelmsen K (2005) Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence. Pharmacogenet Genomics 15(2):115–125PubMedGoogle Scholar
  127. Taavitsainen P, Juvonen R, Pelkonen O (2001) In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene. Drug Metab Dispos 29(3):217–222PubMedGoogle Scholar
  128. Takami K, Saito H, Okuda M, Takano M, Inui KI (1998) Distinct characteristics of transcellular transport between nicotine and tetraethylammonium in LLC-PK1 cells. J Pharmacol Exp Ther 286(2):676–680PubMedGoogle Scholar
  129. Tateishi T, Nakura H, Asoh M, Watanabe M, Tanaka M, Kumai T, Takashima S, Imaoka S, Funae Y, Yabusaki Y, Kamataki T, Kobayashi S (1997) A comparison of hepatic cytochrome P450 protein expression between infancy and postinfancy. Life Sci 61(26):2567–2574PubMedGoogle Scholar
  130. Tyndale RF, Sellers EM (2001) Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. Drug Metab Dispos 29(4 Pt 2):548–552PubMedGoogle Scholar
  131. Tyroller S, Zwickenpflug W, Richter E (2002) New sources of dietary myosmine uptake from cereals, fruits, vegetables, and milk. J Agric Food Chem 50(17):4909–4915PubMedGoogle Scholar
  132. Urakami Y, Okuda M, Maasuda S, Saito H, Inui KI (1998) Functional characteristics and membrane locatlization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J Pharmacol Ther 287:800–805Google Scholar
  133. USDHHS (2001) Risks associated with smoking cigarettes with low machine-measured yields of tar and nicotine. Smoking and Tobacco Control Monographs, U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer InstituteGoogle Scholar
  134. Voncken P, Rustemeier K, Schepers G (1990) Identification of cis-3′-hydroxycotinine as a urinary nicotine metabolite. Xenobiotica 20(12):1353–1356PubMedGoogle Scholar
  135. Wagenknecht LE, Cutter GR, Haley NJ, Sidney S, Manolio TA, Hughes GH, Jacobs DR (1990) Racial differences in serum cotinine levels among smokers in the coronary artery risk development in (young) adults study. Am J Public Health 80(9):1053–1056PubMedGoogle Scholar
  136. Wald NJ, Idle M, Boreham J, Bailey A (1981) Serum cotinine levels in pipe smokers: evidence against nicotine as cause of coronary heart disease. Lancet 2(8250):775–777PubMedGoogle Scholar
  137. Wald NJ, Idle M, Boreham J, Bailey A, Van Vunakis H (1984) Urinary nicotine concentrations in cigarette and pipe smokers. Thorax 39(5):365–368PubMedGoogle Scholar
  138. West R, Hajek P, Foulds J, Nilsson F, May S, Meadows A (2000) A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. Psychopharmacology (Berl) 149(3):198–202Google Scholar
  139. Xia XY, Peng RX, Yu JP, Wang H, Wang J (2002) In vitro metabolic characteristics of cytochrome P-450 2A6 in Chinese liver microsomes. Acta Pharmacol Sin 23(5):471–476PubMedGoogle Scholar
  140. Zevin S, Benowitz NL (1999) Drug interactions with tobacco smoking. An update. Clin Pharmacokinet 36(6):425–438PubMedGoogle Scholar
  141. Zevin S, Jacob P 3rd, Benowitz N (1997) Cotinine effects on nicotine metabolism. Clin Pharmacol Ther 61(6):649–654PubMedGoogle Scholar
  142. Zevin S, Schaner ME, Giacomini KM (1998) Nicotine transport in a human choriocarcinoma cell line (JAR). J Pharm Sci 87:702–706PubMedGoogle Scholar
  143. Zevin S, Jacob P 3rd, Benowitz NL (2000) Nicotine-mecamylamine interactions. Clin Pharmacol Ther 68(1):58–66PubMedGoogle Scholar
  144. Zhang W, Kilicarslan T, Tyndale RF, Sellers EM (2001) Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metab Dispos 29(6):897–902PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  • Neal L. Benowitz
    • 1
  • Janne Hukkanen
    • 2
    • 3
  • Peyton JacobIII
    • 2
    • 3
  1. 1.Division of Clinical Pharmacology and Experimental TherapeuticsUniversity of CaliforniaSan FranciscoUSA
  2. 2.Division of Clinical Pharmacology and Experimental Therapeutics, Medical ServiceSan Francisco General Hospital Medical CenterSan FranciscoUSA
  3. 3.The Departments of Medicine and Biopharmaceutical SciencesUniversity of CaliforniaSan FranciscoUSA

Personalised recommendations